pharma news, views and analysis

in News
Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdict
February 27, 2020 Share
X
Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdict
https://pharmaphorum.com/news/lilly-closes-on-first-line-lung-cancer-use-after-odac-verdict/
in News
NICE backs Celgene’s Revlimid for chemo-free lymphoma therapy
February 27, 2020 Share
X
NICE backs Celgene’s Revlimid for chemo-free lymphoma therapy
https://pharmaphorum.com/news/embargo-001-27-feb-nice-backs-celgenes-revlimid-for-chemo-free-lymphoma-therapy/

Latest News

NICE rejects Roche’s Polivy combination in advanced lymphoma

England’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with

NICE rejects Roche’s Polivy combination in advanced lymphoma

https://pharmaphorum.com/news/nice-rejects-roches-polivy/

Roche hops on Bicycle’s drug discovery platform for cancer

Roche’s recent spate of billion-dollar plus alliances has continued with a deal with UK biotech Bicycle Therapeutics –

Roche hops on Bicycle’s drug discovery platform for cancer

https://pharmaphorum.com/news/roche-hops-on-bicycles-drug-discovery-platform-for-cancer/

GSK begins cancer cell therapy tie-up with Immatics

Cancer biotech Immatics has begun a collaboration with GlaxoSmithKline to develop novel therapies built around its T-cell-based technology.

GSK begins cancer cell therapy tie-up with Immatics

https://pharmaphorum.com/news/gsk-begins-cancer-cell-therapy-tie-up-with-immatics/

See all

Views & analysis

Helsinn’s Riccardo Braglia on the patient perspective in cancer care

Swiss cancer care company Helsinn has become unique in the industry by remaining a family business over three

Helsinn’s Riccardo Braglia on the patient perspective in cancer care

https://pharmaphorum.com/views-analysis-oncology/helsinns-riccardo-braglia-patient-perspective-cancer-care/

Antibody-drug conjugates on the march

One of AstraZeneca’s most decisive moves last year came in March, when it signed a multi-billion dollar deal

Antibody-drug conjugates on the march

https://pharmaphorum.com/views-analysis-oncology/antibody-drug-conjugates-on-the-march/

The three biggest challenges in lung cancer, and how researchers are tackling them

Despite new paradigm-shifting treatments, lung cancer remains a deadly disease – and improving outcomes requires more than just

The three biggest challenges in lung cancer, and how researchers are tackling them

https://pharmaphorum.com/views-and-analysis/the-three-biggest-challenges-in-lung-cancer-and-how-researchers-are-tackling-them/

See all

Debates & Insights

Cost & Management of Oncology Combination Regimens

Overview Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there

Cost & Management of Oncology Combination Regimens

https://pharmaphorum.com/oncology/cost-management-of-oncology-combination-regimens/

Cancer, genomics and personalised medicine: Modelling oncology’s future

Overview The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in

Cancer, genomics and personalised medicine: Modelling oncology’s future

https://pharmaphorum.com/oncology/cancer-genomics-and-personalised-medicine-modelling-the-future-of-oncology/

11/06/2017

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

A unique example of partnership working across the health system, focusses on the service at large, not just the pill, and uses leading-edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore, it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence-based and patient-centric approach to service redesign and resource optimisation.

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

https://pharmaphorum.com/debates-insight-oncology/improving-outcomes-through-industry-partnership-learnings-from-the-cancer-vanguard/

See all

Partner Content

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

RNA Therapeutics

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

https://pharmaphorum.com/partner-content-oncology/attendee-list-released-for-smis-9th-annual-rna-therapeutics/

RNA Therapeutics conference will take place in just 4 weeks!

4 Weeks Until RNA Therapeutics

RNA Therapeutics conference will take place in just 4 weeks!

https://pharmaphorum.com/partner-content-oncology/rna-therapeutics-conference-will-take-place-in-just-4-weeks/

This Week’s Spotlight Features GSK and Advanced Cell Diagnostics

RNA Therapeutics Feb 2018

This Week’s Spotlight Features GSK and Advanced Cell Diagnostics

https://pharmaphorum.com/partner-content-oncology/this-weeks-spotlight-features-gsk-and-advanced-cell-diagnostics/

See all

Search

Advanced Search

Trending